Get the Stockscreener App
3.69
3.40%
-0.13
After Hours:
3.77
0.08
+2.17%
Achieve Life Sciences Inc stock is traded at $3.69, with a volume of 462.43K.
It is down -3.40% in the last 24 hours and down -14.29% over the past month.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
See More
Previous Close:
$3.82
Open:
$3.8
24h Volume:
462.43K
Relative Volume:
3.84
Market Cap:
$126.90M
Revenue:
-
Net Income/Loss:
$-32.94M
P/E Ratio:
-1.1865
EPS:
-3.11
Net Cash Flow:
$-24.95M
1W Performance:
-10.00%
1M Performance:
-14.29%
6M Performance:
-21.32%
1Y Performance:
+8.85%
1-Day Range:
$3.60
$3.96
1-Week Range:
$3.60
$4.205
52-Week Range:
$3.2001
$5.59
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
3.69 | 126.90M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
Achieve Life Sciences Inc Stock (ACHV) Latest News
Achieve Life Sciences, Inc. (NASDAQ:ACHV) down to US$131m market cap, but institutional owners may not be as affected after a year of 0.5% returns - Simply Wall St
Franklin Resources Inc. Sells 2,181,025 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat
Charles Schwab Investment Management Inc. Sells 6,324 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Playing the Long Game To Achieve Financial Success - Yahoo Finance
Molecule AI wins award at BioSpectrum Asia Excellence Awards 2024 - European Pharmaceutical Manufacturer
Puerto Rico air cargo community scoops CEIV Pharma certification - Air Cargo News
Axtria Leads Frost & Sullivan's First Pharmaceutical Commercialization Solutions and Services Industry Radar Report - PR Newswire
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Toshinori Agatsuma, Daiichi’s head of research, passes away - BioCentury
Achieve Life Sciences names new CFO By Investing.com - Investing.com Nigeria
Achieve Life Sciences names new CFO - Investing.com India
Achieve Life Sciences Appoints Mark K. Oki as CFO - TipRanks
GFO-X Announces ABN AMRO Clearing, IMC, Standard Chartered Bank and Virtu Financial as Strategic Partners Ahead of Launch in Q1 2025 - The Manila Times
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer - GlobeNewswire
Achieve Life Sciences, Inc. Appoints Mark Oki as Chief Financial Officer - Marketscreener.com
Achieve Life Sciences Taps Biotech Veteran Mark Oki as New CFO to Lead Financial Strategy - StockTitan
Achieve Life Sciences shares rise on positive FDA meeting outcome By Investing.com - Investing.com Canada
Gene Therapy Market Trends in Market Growth: Size, Demand, - openPR
Kane Biotech Announces $3,000,000 Private Placement Offering - The Manila Times
Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA - GlobeNewswire
Achieve Life Sciences Gets FDA Green Light for Landmark Vaping Cessation Drug Trial | ACHV Stock News - StockTitan
Smoking Cessation and Nicotine Addiction Market Growth Anticipated by 2034 | Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, expected to boost the market - The Globe and Mail
Smoking Cessation and Nicotine Addiction Market Growth - openPR
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Short Interest Down 9.6% in November - MarketBeat
Vaping risks: Study reveals new health concerns - WBBJ-TV
Gene Therapy Market Size, Share, Trends, and Analysis 2024-2032 - openPR
Science Says 3 Strategies Will Help You Achieve Your Big Goals and Live Your Best Life - Inc.
Drug Discovery Outsourcing Services Market to Achieve a Superb - openPR
Clovertex Awarded AWS Life Sciences Competency, Solidifying Leadership in Cloud-Based Solutions for Life Sciences - IT News Online
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives $14.80 Average Price Target from Analysts - Defense World
HC Wainwright Has Optimistic Outlook of OBIO FY2024 Earnings - Defense World
Achieve Life Sciences (NASDAQ:ACHV) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World
FitLife Brands, Inc. Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Brokerages Set Achieve Life Sciences, Inc. (NASDAQ:ACHV) Target Price at $14.80 - MarketBeat
Achieve Life Sciences (NASDAQ:ACHV) Upgraded by RODMAN&RENSHAW to "Strong-Buy" Rating - MarketBeat
Achieve Life Sciences stock rated Buy ahead of NDA submission By Investing.com - Investing.com UK
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences - GlobeNewswire
Achieve Life Sciences to Present at Jefferies, Piper Sandler Healthcare Conferences | ACHV Stock News - StockTitan
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Rodman & Renshaw Begins Coverage on Achieve Life Sciences (NASDAQ:ACHV) - MarketBeat
FY2024 Earnings Estimate for ACHV Issued By Zacks Small Cap - Defense World
Research Analysts Set Expectations for ACHV FY2024 Earnings - MarketBeat
How to achieve a successful drug launch in the first year - MM+M Online
ACHV: Commercialization in Focus - Zacks Small Cap Research
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2024 Earnings Call Transcript - Insider Monkey
How to Take Advantage of moves in (ACHV) - Stock Traders Daily
Achieve qtrly loss per share $0.90 - Reuters
Achieve Life Sciences Inc (ACHV) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Achieve Life Sciences Inc (ACHV) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Achieve Life Sciences (NASDAQ:ACHV) Stock Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Achieve Life Sciences Inc Stock (ACHV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JACOBS CINDY | President & CMO |
Apr 19 '24 |
Option Exercise |
0.00 |
16,250 |
0 |
34,511 |
| Stewart Richard Alistair | Executive Chairman |
Apr 19 '24 |
Option Exercise |
0.00 |
22,500 |
0 |
61,001 |
| Bencich John | CEO |
Apr 19 '24 |
Option Exercise |
0.00 |
25,000 |
0 |
101,724 |
| Stewart Richard Alistair | Executive Chairman |
Mar 04 '24 |
Buy |
4.58 |
10,000 |
45,850 |
38,501 |
| Bencich John | CEO |
Mar 04 '24 |
Buy |
4.58 |
10,000 |
45,850 |
76,724 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):